NeuroRPM gets FDA nod for Apple Watch-based AI remote monitoring app for PD symptoms

NeuroRPM, Inc. has received US Food and Drug Administration (FDA) approval for its Apple Watch-based remote monitoring solution for Parkinson’s disease.

The digital health product, also named NeuroRPM, is an AI-powered disease-management platform, offered as an App on the Apple Watch. It can continuously and passively monitor bradykinesia, tremor, and dyskinesia, the cardinal symptoms of Parkinson's disease.

According to University of Maryland functional neurosurgery director Alexander Ksendzovsky, “The clearance of NeuroRPM is a major milestone in the fight against Parkinson’s disease. This technology will allow for unprecedented insights into the symptoms of Parkinson’s disease using critical health and wellness data from Apple Watch.” Click here to learn more.

Aitia and UCB team up to develop novel Huntington’s treatment

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia aimed at discovering new drug targets and candidates that are linked to clinical endpoints in Huntington’s disease. “We believe that [HD] is overdue for major disruption and breakthroughs from our Gemini Digital Twins,” says Aitia CEO Colin Hill, “which are created from large quantities of multiomic patient data and causal AI.”

The collaboration will combine the use of new drug targets for Huntington’s disease from Aitia’s Gemini Digital Twins with the expertise of UCB in preclinical model systems and drug research in neurodegeneration for advancing new therapies discovery for Huntington’s disease patients. Click here to learn more.

Time spent in nature may reduce hospitalization risk for neurodegenerative diseases

Living near green spaces, parks or bodies of water may help protect older adults from first-time hospitalizations for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, according to a study led by Harvard T.H. Chan School of Public Health. “Increasing physical activity, lowering stress and air pollution levels can be good for your health,” said research fellow and lead author Jochem Klompmaker.

“We can’t cure these diseases, so it’s important to identify modifiable risk factors so that people don’t get sick,” adds Klompmaker. Click here to learn more.

Join the MDF Facebook community

Click here to visit us on Facebook. Like our page and follow us to receive daily updates from MDF in your newsfeed!

Share our posts and help us grow our online community of people living with movement disorders, their caregivers and family members. Facebook also is the place where you can directly interact with MDF. We look forward to hearing from you soon.

Ovary removal when young could raise Parkinson's risk

Women who have both of their ovaries removed before age 43 have an increased risk of developing Parkinson's disease or parkinsonism, according to a recent study. This may owe to the sudden loss of estrogen and other hormones, which causes endocrine dysfunction in premenopausal women, researchers said.

Study results were similar to 2008 research that also linked Parkinson's with removal of both ovaries in younger women, a procedure called bilateral oophorectomy. Click here to learn more.